TPI-1

Research use only, not for human use.

TPI-1 is a SHP-1 inhibitor.

TPI-1, also known as Tyrosine Phosphatase Inhibitor 1, is a SHP-1 inhibitor. TPI-1 selectively increased SHP-1 phospho-substrates (pLck-pY394, pZap70, and pSlp76) in Jurkat T cells but had little effects on pERK1/2 or pLck-pY505 regulated by phosphatases SHP-2 or CD45, respectively. TPI-1 induced mouse splenic-IFN-gamma(+) cells in vitro, approximately 58-fold more effective than sodium stibogluconate, and increased mouse splenic-pLck-pY394 and -IFN-gamma(+) cells in vivo.

SHP-1 has been implicated as a potential cancer therapeutic target. TPI-1 is effective starting at 10 ng/mL in increasing SHP-1 phospho-substrates pLck-pY394. TPI-1 selectively increases SHP-1 phospho-substrates (pLck-pY394, pZap70 and pSlp76) in Jurkat T cells but has little effects on pERK1/2 or pLck-pY505. TPI-1 induces mouse splenic-IFNγ+ cells and induces IFNγ+ cells in human peripheral blood.

TPI-1 inhibits the growth of B16 melanoma tumors in mice at a tolerated oral dose in a T cell-dependent manner but has little effects on B16 cell growth in culture. TPI-1 thus also increases pLck-pY394 and IFNγ+ cells in mice. TPI-1 also inhibits B16 tumor growth and prolongs tumor mice survival as a tolerated s.c. agent.

TPI-1 | TPI 1 | Tyrosine Phosphatase Inhibitor 1

Others

Other Targets

recombinant SHP-1

Cancer

——

79756-69-7

253.08

C12H6Cl2O2

>98% (HPLC)

DMSO : 50 mg/mL 197.57 mM;

c1cc(c(cc1Cl)C1=CC(=O)C=CC1=O)Cl

2-(2,5-dichlorophenyl)-2,5-cyclohexadiene-1,4-dione

(-20℃)

With Ice Pack

≥ 2 years